Nizar J Bahlis

49PUBLICATIONS
222CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)NanomedicineMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Oct 06, 2026
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

|Sep 25, 2026
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.

|Sep 02, 2026
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|Jun 03, 2026
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

Pageof 9

Frequent Collaborators

12 joint publications

Saad Z Usmani

10 joint publications

Aurore Perrot

8 joint publications

Philippe Moreau

8 joint publications

Supratik Basu